Clinical trialsCompany release
FDA allows Alpha Tau to double REGAIN glioblastoma trial to 20 patients
Alpha Tau Medical Ltd. (DRTS) · Thu 19 Nov 2026
Alpha Tau Medical says the US regulator approved an IDE supplement after interim data on Alpha DaRT in recurrent glioblastoma, as the firm reported Q3 2026 results.
Alpha Tau Medical reported third-quarter 2026 results on 19 November, alongside a corporate update on its Alpha DaRT alpha-radiation therapy. The most significant regulatory item was an FDA decision in October 2026 to approve an investigational device exemption (IDE) supplement for the REGAIN trial in recurrent glioblastoma.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Alpha Tau Medical Ltd. ↗
Article written by VigiEye from the official source (Alpha Tau Medical Ltd.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
PMV Pharma reports 48% response rate for rezatapopt in platinum-resistant ovarian cancer
🇺🇸 PMV Pharmaceuticals, Inc. (PMVP) · Fri 20 Nov 2026
J&J's Tremfya beats placebo in Phase 4 STAR axial psoriatic arthritis study at Week 24
Johnson & Johnson EMEA · Fri 20 Nov 2026
Immutep reports 81% 12-month disease-free survival in neoadjuvant soft tissue sarcoma trial
IMMUTEP Ltd (IMMP) · Fri 20 Nov 2026
BfArM lists ArcRoyal field safety notice for procedure trays containing BD Connecta Stopcock
🇩🇪 BfArM field safety notices · Thu 19 Nov 2026
Health Canada posts Type II recall of Philips Bridge Prep Kit over guidewire resistance
🇨🇦 Health Canada · Thu 19 Nov 2026
Olympus updates reprocessing instructions for GF-UC140P-AL5 endoscopic ultrasound gastrovideoscopes in Canada
🇨🇦 Health Canada · Thu 19 Nov 2026